Global Oncology Based Molecular Diagnostics Market Size By Type (PCR, Multiplex PCR), By Application (Breast Cancer, Prostate Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Oncology Based Molecular Diagnostics Market was valued at USD 6.3 billion in 2023 and is projected to reach USD 15.7 billion by 2031, growing at a CAGR of 12.3% during the forecast period from 2023 to 2031. The market is driven by the rising incidence of cancer, increasing demand for personalized medicine, and rapid advancements in molecular diagnostic technologies. Molecular diagnostics play a vital role in oncology by enabling early detection, targeted therapy, and improved prognostic outcomes. The shift toward minimally invasive and precise diagnostic solutions is propelling the adoption of molecular tests across hospitals, diagnostic centers, and research laboratories worldwide.

Drivers:

1. Rising Prevalence of Cancer:

The escalating global cancer burden is significantly contributing to the growth of oncology-based molecular diagnostics. With over 19 million new cancer cases recorded globally in 2023, early and accurate diagnosis through molecular techniques has become a top priority in oncology care.

2. Advancements in Genomic Technologies:

Technological progress in genomics, such as next-generation sequencing (NGS), liquid biopsy, and companion diagnostics, is revolutionizing cancer diagnostics. These innovations enhance diagnostic sensitivity and specificity, leading to more effective patient stratification and treatment selection.

3. Growth of Precision Medicine:

The global trend toward precision medicine emphasizes tailoring medical treatment based on individual genetic profiles. Molecular diagnostics are central to this approach, enabling oncologists to make informed decisions and monitor treatment responses effectively.

Restraints:

1. High Cost of Molecular Diagnostic Tests:

The substantial costs associated with advanced molecular diagnostics, including equipment and reagents, pose a significant barrier to widespread adoption, particularly in low- and middle-income countries.

2. Regulatory and Reimbursement Challenges:

Complex regulatory frameworks and inconsistent reimbursement policies across regions hinder market penetration. Delays in approvals and limited insurance coverage can restrict access to cutting-edge diagnostic technologies.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies in Asia-Pacific, Latin America, and the Middle East & Africa present untapped growth potential. Increasing healthcare investments, awareness programs, and cancer screening initiatives are opening new avenues for market expansion.

2. Integration with Artificial Intelligence (AI):

The convergence of AI with molecular diagnostics is enabling faster data interpretation and enhancing diagnostic accuracy. AI-driven platforms can analyze large datasets to identify cancer biomarkers, accelerating research and clinical decision-making.

Market by System Type Insights:

In 2023, the Polymerase Chain Reaction (PCR) segment held the largest market share among system types. PCR remains a cornerstone in oncology diagnostics due to its affordability, speed, and accuracy in detecting genetic mutations. However, the Next-Generation Sequencing (NGS) segment is anticipated to witness the fastest growth during the forecast period, owing to its ability to analyze multiple genes simultaneously and provide comprehensive insights into tumor genomics.

Market by End-use Insights:

The Hospital segment emerged as the largest end-use segment in 2023, accounting for over 45% of the market share. Hospitals are major centers for cancer diagnosis and treatment, equipped with advanced molecular diagnostic facilities. Meanwhile, diagnostic laboratories are expected to register significant growth due to outsourcing trends and the rising volume of cancer screening tests.

Market by Regional Insights:

North America dominated the global market in 2023, driven by robust healthcare infrastructure, high cancer prevalence, and early adoption of advanced diagnostic technologies. The Asia-Pacific region is projected to experience the highest CAGR during the forecast period, supported by growing healthcare access, rising awareness, and supportive government policies in countries like China and India.

Competitive Scenario:

Key players in the Global Oncology Based Molecular Diagnostics Market include:

Roche Diagnostics

Thermo Fisher Scientific Inc.

QIAGEN N.V.

Illumina, Inc.

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.

Guardant Health, Inc.

Myriad Genetics, Inc.

Foundation Medicine, Inc.

These companies are focusing on strategic collaborations, product innovation, and regulatory approvals to strengthen their market position. Notable developments include:

In 2024, Thermo Fisher launched an expanded NGS oncology panel for rare mutations.

In 2023, Roche Diagnostics received FDA approval for its liquid biopsy test for early breast cancer detection.

In 2022, Illumina entered a partnership with Merck to co-develop diagnostics for immunotherapy response prediction.

Scope of Work – Global Oncology Based Molecular Diagnostics Market

Report Metric Details

Market Size (2023) USD 6.3 billion

Projected Market Size (2031) USD 15.7 billion

CAGR (2023–2031) 12.3%

Market Segments By System Type (PCR, NGS, Microarray, ISH), By End-use (Hospitals, Labs)

Growth Drivers Rising cancer prevalence, genomic innovation, and shift toward precision medicine

Opportunities AI integration, emerging market expansion

Key Market Developments:

May 2024: Thermo Fisher Scientific launched an expanded oncology panel integrating AI-assisted variant calling for rare cancers.

August 2023: Guardant Health introduced a liquid biopsy solution that enables early-stage cancer detection through a simple blood test.

March 2022: QIAGEN partnered with leading oncology centers in Europe to implement companion diagnostics for targeted therapies.

FAQs:

1) What is the current market size of the Global Oncology Based Molecular Diagnostics Market?

The market was valued at USD 6.3 billion in 2023.

2) What is the major growth driver of the Global Oncology Based Molecular Diagnostics Market?

The major growth driver is the rising prevalence of cancer and the increasing demand for personalized medicine.

3) Which is the largest region during the forecast period in the Global Oncology Based Molecular Diagnostics Market?

North America is the largest region due to early adoption of molecular diagnostics and a high cancer burden.

4) Which segment accounted for the largest market share in Global Oncology Based Molecular Diagnostics Market?

The PCR segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Oncology Based Molecular Diagnostics Market?

Key players include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, and Abbott Laboratories.